Q4 revenue +374% Healwell AI (AIDX.TO TSX) C$0.90 intraday 20 Mar 2026: margin test

Healwell AI reported Q4 revenue up 374.00% year over year. AIDX.TO stock trades at C$0.90 intraday on 20 Mar 2026. The move follows a Q4 top line of C$32.20 million and full-year revenue of C$103.80 million in 2025. Investors reacted while margins and cash flow drew fresh scrutiny. This note connects Q4 growth to intraday price action, balance sheet metrics, technical setup, and model forecasts for the TSX-listed Healwell AI in Canada.

AIDX.TO stock: intraday price action and market context

AIDX.TO opened at C$0.94 and trades between C$0.88 and C$0.94 today. Volume sits at 354,239 shares versus an average of 563,025. The stock is down -3.23% today as traders weigh the revenue beat against widening losses. The company’s market cap is C$250,557,991.00, and shares outstanding are 278,397,768.

AIDX.TO stock: what the Q4 earnings reveal

Healwell AI reported C$32.20 million in Q4 revenue, a 374.00% increase versus year ago. Full-year 2025 revenue reached C$103.80 million, up 166.35% year over year. Net loss widened to C$47.11 million in 2025, pressuring margins despite the top-line surge. The earnings call highlights strategic acquisitions and expanded AI services as drivers. Read the transcript at Investing.com.

Balance sheet, cash flow and valuation signals for AIDX.TO stock

Key ratios show valuation and liquidity strains. EPS is -0.23 and reported PE is -3.91. Price-to-sales is 2.47 and price-to-book is 1.76. The current ratio stands at 0.85, below typical healthcare peers. Debt-to-equity is 0.74, and cash per share is C$0.07. These metrics show growth with tight near-term liquidity and negative operating cash flow per share of -0.10.

Technical setup and trading metrics for AIDX.TO stock

Technicals show a mixed but actionable picture. RSI is 57.38, indicating neutral momentum. The 50-day average is C$0.80 and the 200-day average is C$1.15. ADX reads 38.94, signalling a strong trend. Bollinger bands sit at 0.57 to 1.06, and ATR is 0.06. Traders may watch a break above C$1.06 for upside confirmation or a move below C$0.72 for downside confirmation.

Meyka AI rates AIDX.TO with a score out of 100 and valuation view

Meyka AI rates AIDX.TO with a score out of 100: 62.07 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a quarterly price of C$0.72, implying -20.00% versus the current C$0.90. Forecasts are model-based projections and not guarantees. For direct company details see the TSX quote on CNBC and our internal page at Meyka AIDX.TO stock page.

Risks and catalysts shaping AIDX.TO stock

Near-term risks include negative operating cash flow and margin pressure from acquisitions. Receivables days are long at 135.18, which may strain working capital. Catalysts include further AI contract rollouts, integration progress with WELL Health Technologies, and quarterly margin improvement. Regulatory developments in healthcare AI remain binary catalysts for the stock.

Final Thoughts

Key takeaways for AIDX.TO stock: Healwell AI delivered a +374.00% Q4 revenue surge, but the company still reports negative earnings and tight liquidity. The stock trades intraday at C$0.90, below its 200-day average of C$1.15, and within striking distance of year high C$1.81. Meyka AI’s model projects a quarterly forecast of C$0.72, implying -20.00% from today’s price. Our scenario price targets are conservative C$0.60 (implied -33.33%), base C$1.20 (implied +33.33%), and optimistic C$1.80 (implied +100.00%). These levels reflect balance sheet risk, recent acquisition growth, and the sector’s valuation range. Forecasts are model-based projections and not guarantees. Use intraday technical signals to time trades and monitor upcoming cash flow updates closely. Meyka AI provides this AI-powered market analysis platform view for informed decision making, not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.